Angiogenesis and antiangiogenic agents in cervical cancer

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 2237-2248

  Tomao, Federica ^a   Papa, Anselmo ^a   Rossi, Luigi ^a   Zaccarelli, Eleonora ^a   Caruso, Davide ^a   Zoratto, Federica ^a   Panici, Pierluigi Benedetti ^a   Tomao, Silverio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Cervical cancer; Human papillomavirus; Target therapies

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BRIVANIB ALANINATE; CAPECITABINE; CARBOPLATIN; CD31 ANTIGEN; CISPLATIN; DASATINIB; ENDOGLIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; IRINOTECAN; LAPATINIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PF 4856884; PLACEBO; SORAFENIB; SUNITINIB; TOPOTECAN; TRANSFORMING GROWTH FACTOR BETA; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A;

ADVANCED CANCER; ANOREXIA; BLEEDING; BLOOD VESSEL PERMEABILITY; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DOSE RESPONSE; DRUG SAFETY; DRUG TARGETING; EPISTAXIS; FATIGUE; FISTULA; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY CANCER; LOW DRUG DOSE; METASTASIS; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUROTOXICITY; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL EDEMA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

EID: 84919330922     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S68286     Document Type: Review

References (124)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
3. Howlander N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2009. Bethesda, MD, USA: National Cancer Institute; 2012.
4. Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 2007;98:1505–1511.
5. Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J, Kerbel RS. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene. 2000; 19: 4611–4620.
6. Lee JS, Kim HS, Jung JJ, Lee MC, Park CS. Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression. Gynecol Oncol. 2002;85:469–475.
7. Lee JS, Kim HS, Park JT, Kim YB, Lee MC, Park CS. Expression of vascular endothelial growth factor in the progression of cervical neoplasia and its relation to angiogenesis and p53 status. Anal Quant Cytol Histol. 2003;25:303–311.
8. Toussaint-Smith E, Donner DB, Roman A. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene. 2004;23:2988–2995.
9. Wu MP, Tzeng CC, Wu LW, Huang KF, Chou CY. Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis. Cancer J. 2004;10:27–32.
10. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994;265:1582–1584.
11. Kim MK, Kim HS, Kim SH, et al. Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment. Biochem Pharmacol. 2010;80:1930–1935.
12. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–364.
13. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186.
14. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4–6.
15. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–1613.
16. Marnitz S, Dowdy S, Lanowska M, Schneider A, Podratz K, Köhler C. Exenterations 60 years after first description: results of a survey among US and German Gynecologic Oncology Centers. Int J Gynecol Cancer. 2009;19:974–977.
17. Tran PT, Su Z, Hara W, Husain A, Teng N, Kapp DS. Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2007;69:504–511.
18. Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J. Cisplatinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer. 1981;48:899–903.
19. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23: 1011–1027.
20. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16:159–178.
21. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell. 1991;66: 1095–1104.
22. Traini S, Piccolo E, Tinari N, et al. Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. Mol Cancer Ther. 2014;13: 916–925.
23. Napoletano C, Bellati F, Tarquini E, et al. MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy. Am J Obstet Gynecol. 2008;198:993. e1–e7.
24. Fujii T, Kuwano H. Regulation of the expression balance of angiopoietin-1 and angiopoietin-2 by Shh and FGF-2. In Vitro Cell Dev Biol Anim. 2010;46:487–491.
25. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 1992;189:824–831.
26. Compagni A, Wilgenbus P, Impagnatiello MA, Cotten M, Christofori G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 2000;60:7163–7169.
27. Giavazzi R, Sennino B, Coltrini D, et al. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol. 2003;162:1913–1926.
28. Daniele G, Corral J, Molife LR, de Bono JS. FGF receptor inhibitors: role in cancer therapy. Curr Oncol Rep. 2012;14:111–119.
29. Evans C, Dalgleish AG, Kumar D. Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther. 2006;24: 1163–1177.
30. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol. 2007;2:251–275.
31. Hopfl G, Ogunshola O, Gassmann M. HIFs and tumors – causes and consequences. Am J Physiol Regul Integr Comp Physiol. 2004;286: 608–623.
32. Brown LM, Cowen RL, Debray C, et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol. 2006;69:411–418.
33. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795–803.
34. Ohm JE, Gabrilovich DI, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003;101:4878–4886.
35. Bellati F, Napoletano C, Gasparri ML, et al. Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms. Crit Rev Oncol Hematol. 2012;83:35–46.
36. Papamichail M, Perez SA, Gritzapis AD, Baxevanis CA. Natural killer lymphocytes: biology, development and function. Cancer Immunol Immunother. 2004;53:176–186.
37. Dikov MM, Ohm JE, Ray N, et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol. 2005;174:215–222.
38. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024–1028.
39. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579–591.
40. Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 2010;10:575–585.
41. Karamysheva AF. Mechanisms of angiogenesis. Biochemistry. 2008;73: 751–762.
42. Nasarre P, Thomas M, Kruse K, et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res. 2009;69:1324–1333.
43. White RR, Shan S, Rusconi CP, et al. Inhibition of rat corneal angiogenesis by a nuclease resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci USA. 2003;100:5028–5033.
44. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell. 2004;6:507–516.
45. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284:1994–1998.
46. Zagzag D, Hooper A, Friedlander DR, et al. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol. 1999;159:391–400.
47. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA. 2002;99:11205–11210.
48. Zhang L, Yang N, Park JW, et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res. 2003;63:3403–3412.
49. Coxon A, Rex K, Sun J. Combined treatment of angiopoietin and VEGF pathway antagonists enhances antitumor activity in preclinical models of colon carcinoma. Abstract 1113 presented at the 2008 American Association for Cancer Research annual meeting, April 12–16, 2008, San Diego, CA, USA.
50. Hughes P, Polverino A, Oliner J, Kendall R. Angiopoietin-2 antagonists of anti-angiogenic therapy. In: Marme D, Fusenig N, editors. Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy. Berlin, Germany: Springer; 2007.
51. Venneri MA, De Palma M, Ponzoni M, et al. Identification of proangio-genic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood. 2007;109:5276–5285.
52. Du R, Lu KV, Petritsch C, et al. HIF-1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008;13:206–220.
53. Hashizume H, Falcón BL, Kuroda T, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 2010;70:2213–2223.
54. Stafl A, Mattingly RF. Angiogenesis of cervical neoplasia. Am J Obstet Gynecol.1975;121:845–851.
55. Vici P, Mariani L, Pizzuti L, et al. Emerging biological treatments for uterine cervical carcinoma. J Cancer. 2014;5:86–97.
56. Smith-McCune KK, Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res. 1994;54:800–804.
57. Cooper RA, Wilks DP, Logue JP, et al. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin Cancer Res. 1998;4:2795–2800.
58. Rubatt JM, Darcy KM, Hutson A, et al. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;112:469–474.
59. Cheifetz S, Bellón T, Calés C, et al. Endoglin is a component of the transforming growth factor-receptor system in human endothelial cells. J Biol Chem. 1992;267:19027–19030.
60. Vici P, Mariani L, Pizzuti L, et al. Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res. 2014;33:29.
61. Zijlmans HJ, Fleuren GJ, Hazelbag S, et al. Expression of endoglin (CD105) in cervical cancer. Br J Cancer. 2009;100:1617–1626.
62. Monk BJ, Sill MW, Burger RA. Phase II trial of bevacizumab in the treatment of recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:S23.
63. Randall LM, Monk BJ, Darcy KM, et al. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 2009;112:583–589.
64. Obermair A, Wanner C, Bilgi S, et al. Tumor angiogenesis in stage IB cervical cancer: correlation of microvessel density with survival. Am J Obstet Gynecol. 1998;178:314–319.
65. West CM, Cooper RA, Loncaster JA, Wilks DP, Bromley M. Tumor vascularity: a histological measure of angiogenesis and hypoxia. Cancer Res. 2001;61:2907–2910.
66. Kainz C, Speiser P, Wanner C, et al. Prognostic value of tumour microvessel density in cancer of the uterine cervix stage IB to IIB. Anticancer Res. 1995;15:1549–1551.
67. Rutgers JL, Mattox TF, Vargas MP. Angiogenesis in uterine cervical squamous cell carcinoma. Int J Gynecol Pathol. 1995;14:114–118.
68. Hutchison GJ, Valentine HR, Loncaster JA, et al. Hypoxia-inducible factor lalpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res. 2004;10:8405–8412.
69. Dobbs SP, Hewett PW, Johnson IR Carmichael J, Murray JC. Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia. Br J Cancer. 1997;76:1410–1415.
70. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 1995;147:9–19.
71. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967–974.
72. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.
73. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987–989.
74. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 2004;46:293–298.
75. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2000;37:443–448.
76. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12:1232–1235.
77. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003;63:812–816.
78. Kim YH, Kim MA, Park IA, et al. VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival. Gynecol Oncol. 2010;119:232–236.
79. Willmott LJ, Monk BJ. Cervical cancer therapy: current, future and anti-angiogenesis targeted treatment. Expert Rev Anticancer Ther. 2009;9:895–903.
80. Nakamura M, Bodily JM, Beglin M, Kyo S, Inoue M, Laimins LA. Hypoxia specific stabilization of HIF-lalpha by human papilloma viruses. Virology. 2009;387:442–448.
81. Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol. 2011;121:230–238.
82. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676.
83. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400.
84. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.
85. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.
86. Robert NJ, Diéras V Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–1260.
87. Chinot OL, de La Motte Rouge T, Moore N, et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011;28:334–340.
88. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–2483.
89. Tomao F, Papa A, Rossi L, et al. Current status of bevacizumab in advanced ovarian cancer. Onco Targets Ther. 2013;6:889–899.
90. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 2009;6: 507–518.
91. Wright JD, Viviano D, Powell MA, et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol. 2006;103:489–493.
92. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:1069–1074.
93. Kikuchi Y, Takano M, Goto T, et al. Effects of weekly bevacizumab and paclitaxel/carboplatin with or without sorafenib on heavily pretreated patients with recurrent or persistent cervical cancer. J Clin Oncol.2011;29 Suppl:Abstr 5085.
94. Takano M, Kikuchi Y, IkedaY, et al. Effects of weekly bevacizumab and gemcitabine/oxaliplatin with or without dasatinib on heavily pretreated patients with recurrent or persistent cervical cancer. J Clin Oncol. 2012; 30:Suppl:Abstr e15579.
95. Schefter TE, Winter K, Kwon JS, et al. A Phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys. 2012;83:1179–1184.
96. National Cancer Institute. Bevacizumab, radiation therapy, and cisplatin in treating patients with previously untreated locally advanced cervical cancer. ClinicalTrials.gov identifier NCT00369122. Available from: http://clinicaltrials.gov/show/NCT00369122. Accessed October 8, 2014.
97. Zighelboim I, Wright JD, Gao F, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013;130:64–68.
98. Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer. JV Engl J Med. 2014;370:734–743.
99. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist. 2006;11:753–764.
100. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer They. 2003;2:471–478.
101. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–337.
102. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101:3597–3605.
103. Mackay HJ, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol. 2010;116:163–167.
104. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–1068.
105. Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010;28:3562–3569.
106. Monk BJ, Pandite LN. Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2011;29:4845.
107. Diaz-Padilla I, Siu LL. Brivanib alaninate for cancer. Expert Opin Investig Drugs.2011;20:577–586.
108. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–129.
109. Tomao F, Papa A, Rossi L, et al. Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer. Expert Opin Investig Drugs. 2014;23:37–53.
110. Cai ZW, Zhang Y, Borzilleri RM, et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2 aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem. 2008;51:1976–1980.
111. Liang G, Chen G, Wei X, Zhao Y, Li X. Small molecule inhibition of fibroblast growth factor receptors in cancer. Cytokine Growth Factor Rev. 2013;24:467–475.
112. Bhide RS, Lombardo LJ, Hunt JT, et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther. 2010;9:369–378.
113. Bhide RS, Cai ZW, Zhang YZ, et al. Discovery and preclinical studies of(R)-1-(4-(4-fluoro-2-methyl-1hindol-5yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol(BMS 540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem. 2006;49:2143–2146.
114. Gynecologic Oncology Group. Brivanib in treating patients with persistent or recurrent cervical cancer. Available from: Clinicaltrials. gov identifier NCT01267253. Accessed October 9, 2014.
115. Candelaria M, Arias-Bonfill D, Chavez-Bianco A, et al. Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha. Int J Gynecol Cancer. 2009;19:1632–1637.
116. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592–603.
117. Shim WS, Teh M, Bapna A, et al. Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp Cell Res. 2002;279:299–309.
118. Coxon A, Bready J, Min H, et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody Mol Cancer Ther. 2010;9:2641–2651.
119. Lu JF, Rasmussen E, Karlan BY, et al. Exposure response relationship of AMG386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemother Pharmacol. 2012;69:1135–1144.
120. Monk BJ, Proveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomized, multicentre, double-bind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:799–808.
121. Bamias A, Pignata S, Pujade-Lauraine E. Angiogenesis: a promising therapeutic target for ovarian cancer. Crit Rev Oncol Hematol. 2012;84:314–326.
122. Van Cutsem E, Tabernero J, Lakomy R, et al. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262-VELOUR). Presented at the 13th World Congress on Gastrointestinal Cancer, June 22–25, 2011, Barcelona, Spain.
123. Peeters M, Strickland AH, Lichinitser M, et al. A randomized, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer. 2013;108:503–511.
124. Tan SJ, Juan YH, Fu PT, et al. Chemotherapy with low-dose bevacizumab and carboplatin in the treatment of a patient with recurrent cervical cancer. Eur J Gynaecol Oncol. 2010;31(3):350–353.